

2025 RETAIL DRUG OUTLET and INSTITUTIONAL DRUG OUTLET COMPOUNDING PHARMACY SELF-INSPECTION FORM

ATTENTION: PHARMACIST-IN-CHARGE (PIC)

Failure to complete this form by July 1, 2025, and within 15 days of becoming PIC, may result in disciplinary action (OAR 855-115-0210(1)(h)).

Please note: This is not a standalone self-inspection form. It is to be completed in conjunction with the appropriate Drug Outlet Self-Inspection Form (i.e., Retail, Institutional, Non-Resident, etc.).

Requirements: Oregon law states the PIC and all pharmacists on duty are responsible for ensuring the pharmacy is compliant with all applicable state and federal laws and rules. This form must be provided to the board immediately upon request at the time of inspection and retained in compliance with OAR 855-104-0055.

Scope: The primary objective of completing the self-inspection is to identify and correct areas of non-compliance with any state and federal laws and rules. This process is not exhaustive, and laws and rules may change between annual updates to this form. Subsequently, it is your responsibility to ensure compliance with any changes, or applicable laws and rules, not referenced herein.

Internal Use: Following completion of the self-inspection form, ensure it is signed and dated by the PIC, reviewed with all pharmacy staff, and filed in a conspicuous manner (DO NOT SEND to the agency office). It is advisable to create a binder for this form, using tabs to organize and group documents where possible. Otherwise, please CLEARLY indicate on the form where auxiliary documents are located.

Agency Use: During an inspection, Compliance Officers use the self-inspection form as a general guide to assess pharmacy compliance. The PIC and all pharmacy staff should be prepared and able to retrieve this form and locate any auxiliary documents referenced within at the time of inspection.

Email all compliance-related questions to: pharmacy.compliance@bop.oregon.gov

2025 RETAIL DRUG OUTLET and INSTITUTIONAL DRUG OUTLET COMPOUNDING PHARMACY SELF-INSPECTION FORM

Please list where the following items are specifically located inside the pharmacy. Once located, ensure each is compliant, and reflects currents practices within the outlet (if an item is not applicable, indicate with N/A). Unless otherwise specified, documents are to be retained for 3 years (the first of which must be on site) and must be provided to the Board upon request, as outlined in OAR 855-104-0055.

Compounding References (please list name(s) and location)

Initial an	nd Ongoing Training, Certificates and Documentation
• 1	Nonsterile Compounding □ N/A
• (Sterile Compounding N/A
	Media Fill / Gloved Fingertip Competency
Policies	and Procedures
•	Training, Evaluation and Requalification
	o Aseptic Manipulation Skills Testing, Gloved Fingertip testing and related assessments
• (Creating Compounding and Master Formulation Records (with documented pharmacist approval)
• 1	Hygiene
• (Cleaning Activities (to include sanitizing and disinfecting)
• (Gowning and Garbing Material Selection, Handling, and Storage
• I	Handling, Packaging, Storage, and Transport of completed compounded preparations.
	Continuous Quality Assurance and Quality Control (to include release-testing, end-product evaluation, and quantitative/qualitative testing)
• /	Adverse Event Reporting and Recalls

Testing (equipment, environmental, and product)

- Equipment Certifications and Calibrations
- Environmental Monitoring (air and surface sampling for viable and non-viable particles, as appropriate)
- Bulk Chemical Certificates of Analysis

Records

- Cleaning Logs
- Master Formulation Records
- Compounding Worksheets

INSTRUCTIONS:

Verify compliance of each section by marking the corresponding box. Should any non-compliance be identified, rectify the deficiencies and record the correction date

General Requirements

Yes	No	N/A			Rule Reference
			1.	Does the pharmacy have access to the most current USP Chapters?	OAR 855-041-1035 OAR 855-045-0200 OAR 855-045-0205
				Note: USP Chapters updated with effective date of 11/1/2023.	
			2.	Does the pharmacy have compounding accreditation?	
				If yes, please specify (e.g., NABP, PCAB, Joint Commission):	
				Date of the last accreditation:/// (Attach a copy of last accreditation to this form)	

		N/A			Rule Reference
			3.	What type of non-sterile compounding is performed? (check all that apply)	
				 □ Topical Creams □ Compounding Kits □ Hazardous / HRT □ Veterinary □ Other: 	
			4.	What type of sterile compounding is performed? (check all that apply)	
				□ IV's □ TPN □ Intrathecal / Epidural □ Eye Drops □ Lyophilization □ Pellets □ Chemotherapy □ Hazardous □ Other: □	
			cies a	nd Procedures	Dula Deference
Yes	No	N/A		-	Rule Reference ORS 689.486(6)
			cies a	Describe the pharmacy's process for the supervision of compounding. Note: A technician may only compound under the supervision, direction, and control of a pharmacist.	Rule Reference ORS 689.486(6)

res	INO	IN/A			Rule Reference
			7.	If the pharmacy extends BUDs beyond USP standards, please describe the QA process utilized to ensure sterility and/or stability are maintained:	OAR 855-045-0220
				How often are samples sent for testing to an independent laboratory to account for the facility's unique processes?	

Compounding Operations

Yes	No	N/A			Rule Reference
			8.	Are bulk drug substances acquired only from Board-registered manufacturers or wholesalers, and have the required certificate of analysis?	e-CFR 503A Guidance Document 503B Guidance Document
			9.	Is the pharmacy only using active pharmaceutical ingredients (APIs) and excipients that are <u>approved for use in humans</u> , not laboratory/research grade products?	e-CFRs
			10.	Does the pharmacy batch compound products?	
				If so, what type(s)? \square Sterile \square Non-sterile	
			11.	Does the pharmacy provide samples of compounded products to prescribers, or sell compounded products OTC?	OAR 855-060-0001 OAR 855-045-0210
				If yes, attach a copy of the pharmacy's manufacturing registrations from both the FDA and Board of Pharmacy.	
			12.	Does the pharmacy handle hazardous drugs (which includes receiving, storing, compounding, dispensing, etc.)?	OAR 855-045-0200
				If yes, is the pharmacy currently in compliance with USP 800?	

Compounding Records

Yes	No	N/A		Rule Reference
			Do the master formulation records include the following required elements, where appropriate? (mark each box once confirmed)	OAR 855-045-0270
			 □ Complete instructions for preparing the product, including equipment, supplies, and description of compounding steps □ Ingredients, quantities, and calculations used to determine/verify those amounts □ Sterilization method, if required (such as steam, dry heat, radiation, filtration, etc.) □ Quality control procedures and expected results □ Compatibility and stability information, including references □ BUD and storage requirements, including references □ Appropriate ancillary information such as cautionary statements, hazardous drug warning labels, etc. □ Name, strength, dosage form, and physical description of the final preparation Note: Be prepared to provide documentation at the time of 	
			inspection.	
			14. Do completed compounding records include all of the following required elements? (mark each box once confirmed) □ Master formulation record reference for the preparation, when applicable □ Name, quantity (weight or measurement), manufacturer's lot number and expiration date for all ingredients used, including base, diluent, primary excipient, etc. □ Identity of all personnel involved in each step of the process □ Pharmacist documented verification of compounded product accuracy including the correct formula, calculations, and the correct measurements and drugs used □ Name, strength, dosage form, and physical description of final preparation □ Date and time prepared □ Quantity prepared □ Pharmacy unique lot number □ BUD and storage requirements (with reference, if different from master formulation record) □ Documentation of any quality control issues, adverse reactions, or preparation problems (including those reported by the patient, caregiver, or other person), with corresponding corrective actions □ Records of compound dispensation or transfer □ Any other information, as required by pharmacy policies and procedures	OAR 855-045-0270
_				
Compo	ounde	d Sterile	e Products (CSP's) General Requirements	
Yes	No			Rule Reference
		15.	How often does the pharmacy test <u>all</u> compounding personnel (including verifying pharmacists) in aseptic manipulative skills, gowning and garbing, and gloved fingertip sampling?	OAR 855-045-0220 OAR 855-045-0270
<u>L</u>		l		

Yes	No			Rule Reference
		16.	Do compounding procedures include requirements for use of gowns, shoe covers, hair covers, sterile gloves, and masks?	OAR 855-045-0220 OAR 855-045-0200
			Note : Makeup, jewelry, and artificial nails/fingernail polish are not permitted in the buffer room.	
		17.	Are CSP's prepared in an ISO 5 certified Primary Engineering Control (PEC)?	OAR 855-045-0200
		18.	Are all ISO classified areas checked and certified per USP standards every 6 months and whenever a PEC is relocated, or the physical structure of the buffer room or anteroom has been altered?	OAR 855-045-0220
		19.	Have the ISO classified areas had any growth above action levels in the past year?	OAR 855-045-0220 OAR 855-045-0270
			If yes, please identify the date and steps taken to remediate.	
		20.	Have there been any other issues identified in the ISO classified spaces in the past year? If yes, please explain.	OAR 855-045-0200
		21.	Is ISO determination taken under dynamic conditions while simulated compounding is occurring?	OAR 855-045-0200
		22.	Are surfaces and equipment in buffer room and anteroom nonporous, smooth, non-shedding, impermeable, cleanable, and resistant to disinfectants?	OAR 855-045-0200
		23.	Does the pharmacy document environmental monitoring to ensure that the compounding environment is properly maintained, including temperature, humidity, and pressure differentials?	OAR 855-045-0270
		24.	Does the pharmacy have policies and procedures that include routinely monitoring the compounding environment for microbial or fungal growth?	OAR 855-045-0220 OAR 855-045-0270
		25.	How often does the pharmacy perform surface sampling?	OAR 855-045-0220 OAR 855-045-0270
			What is the incubation time and temperature ?	
		26.	In addition to regular labeling requirements, do CSP labels include all of the following elements? (mark each box once confirmed) □ The generic or official name of each active ingredient	OAR 855-045-0240

res	NO			Ruie Reference
			□The strength or concentration of each active ingredient (to include primary solution for a sterile parenteral preparation) □The dosage form and route of administration □Rate of infusion (for a sterile parenteral preparation) □The total quantity of the drug product □A BUD, compliant with current USP standards □Storage and handling instructions, cautionary information or warnings as necessary to promote proper and safe use, and any relevant drug-specific information?	
		27.	In ISO 7 and 8 areas, are floors and work surface areas cleaned <u>daily</u> , and are walls, ceilings, and shelving cleaned at least <u>monthly</u> ?	OAR 855-045-0200
		28.	Who performs cleaning and disinfecting of ISO classified areas in the pharmacy?	OAR 855-045-0220 OAR 855-045-0270
			Are these individuals trained in accordance with USP 797?	
		29.	What agents are used to clean and disinfect the PEC? How often are they used? What is the dwell time?	OAR 855-045-0220 OAR 855-045-0270
	polici		o the best of my knowledge, this outlet is compliant with all applicable to the control of the c	
Signat	ure of	PIC:		
Printed	d Name	e of PIC:		